INTRODUCTION
The intestine represents a major gateway for potential pathogens, which also contains dietary antigens and an extensive and diverse microbial flora that need to be tolerated. Due to these requirements, the gut constitutes the largest lymphoid organ in the body, encompassing an extensive network of secondary lymphoid organs and is home to an enormous number of lymphocytes (Izcue et al., 2009) . Intestinal immune responses take place in the epithelium, lamina propria, and gut-associated lymphoid tissue (GALT). The gut harbors several intestine-specific subpopulations specialized in antigen presentation, antimicrobial immunity, and maintenance of tolerance. Breakdown in the regulatory pathways leads to chronic intestinal inflammation (Kaser et al., 2010) . For example, dysregulation of mucosal T cell responses may cause a loss of tolerance, leading to harmful intestinal inflammation reminiscent of human inflammatory bowel disease (IBD) (Strober et al., 2002) . Moreover, the regulatory T cells (Tregs) play a critical role in the maintenance of intestinal homeostasis and self-tolerance (Asseman et al., 1999; Sakaguchi, 2005) . However, how the intestinal innate immune system is regulated during the intestinal inflammation remains elusive.
Innate lymphoid cells (ILCs) are located in mucosal surfaces to potentiate immune responses, sustain mucosal integrity and promote lymphoid organogenesis (Diefenbach et al., 2014; Eberl et al., 2015) . Group 1 (ILC1) cells are characterized by their capacity to secrete interferon g (IFN-g) responding to interleukin-12 (IL-12), IL-15, and IL-18 (Gordon et al., 2012; Klose et al., 2014) . Group 2 (ILC2) cells generate type 2 T helper (Th2) cell cytokines, such as IL-5, IL-9, and IL-13, in response to IL-25 and IL-33 stimulation (Brestoff et al., 2015; Moro et al., 2010) . Group 3 (ILC3) cells produce IFN-g, IL-17, and IL-22 following stimulation with IL-1b and IL-23 (Buonocore et al., 2010; Klose et al., 2013) . Given that ILCs produce substantial effector cytokines when stimulated, they play a critical role in the regulation of type 1, type 2, and type 3 (or Th17 cell) responses, controlling host protective immunity and intestinal homeostasis (Bedoui et al., 2016; Gasteiger and Rudensky, 2014; Shih et al., 2016) .
Accumulating evidence shows that inflammatory responses can be induced and regulated independently of adaptive immunity . Rag (V[D]J recombination activation gene)-deficient mice develop colitis after treatment with anti-CD40 antibody or dextran sodium sulfate (DSS) (Buonocore et al., 2010; Wirtz et al., 2007) . Intraepithelial ILC1s undergo expansion and produce large amounts of IFN-g in the human Crohn's disease. Blocking of ILC1 with anti-NK1.1 antibody in mice is able to attenuate colitis (Fuchs et al., 2013) . In addition, 
CD45
+ lymphocytes were gated out for analysis of CD127 versus IL-10-GFP. The total number of ILCregs was calculated and is shown as the mean ± SD. sLP, small intestine lamina propria; sIE, small intestine intra-epithelial
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ILC3s are implicated in the innate intestinal inflammation via secretion of IL-17 and IL-22. IL-17-producing ILC3s are responsible for the pathogenesis of Tbx21
Rag2
À/À ulcerative colitis mice (Garrett et al., 2007; Powell et al., 2012) . Depletion of ILC3s by anti-Thy1 antibody abrogates innate colitis (Buonocore et al., 2010) , suggesting a critical role of ILC3s in the pathogenesis of intestinal inflammation. However, it is unknown whether a regulatory subset of ILCs exists and how they function in the regulation of intestinal inflammation. Here, we identify a novel regulatory subpopulation of ILCs (called ILCregs) that exists in the gut and expands in the intestine following pathogenic stimulation. ILCregs exert an inhibitory role in the innate immune response against intestinal inflammation.
RESULTS

ILCregs Exist in Mouse and Human Intestines
Given that Treg cell-mediated suppression through secretion of their feature cytokines IL-10 and TGF-b (Izcue et al., 2009; Josefowicz et al., 2012) , we then gated out Lin À CD45 + CD127 + ILCs from multiple tissues in IL-10-GFP reporter mice and analyzed IL-10 expression (Kamanaka et al., 2006) . We noticed that a unique subset of ILCs constitutively expressed IL-10 in the intestine ( Figures 1A and S1A ). These Lin À CD45 + CD127 + IL-10 + ILCs were mainly located in the lamina propria of the small intestine (sLP), and some of them in the small intestinal epithelium (sIE) and colon lamina propria (cLP) ( Figure 1A ). Lin such as CD25 (IL-2Ra) and CD90 (Thy1). This population also highly expressed IL-2Rg and Sca-1, but lacked ILC1 markers (NK1.1 and NKp46), ILC2 markers (ST2 and KLRG1), ILC3 markers (NKp46, CD4, and RORgt), or other leukocyte lineage markers (Gury-BenAri et al., 2016; Robinette et al., 2015) ( Figures  1D and S1C ). These Lin À CD45 + CD127 + IL-10 + ILCs represented a new IL-10-producing ILC population that we have named regulatory ILCs (ILCregs). IL-10-producing ILCregs were further confirmed through imaging flow cytometry by using anti-IL-10 antibody ( Figure 1E ). Furthermore, ILCregs with co-expression of CD127 and IL-10 indeed existed in mouse small and large intestines by immunofluorescence staining ( Figures 1F and S1D ). These observations were further validated through immunohistochemical staining ( Figure 1G ). In addition, ILCregs also existed in the human intestine from biopsies ( Figures 1H, 1I , and S1E Figure 2A ). Of note, ILCregs do express high levels of Il10 and several ILC feature markers, including Il7r (encoding CD127), Il2ra (encoding CD25), Il2rg, and Ly6a (encoding Sca-1), which is consistent with our previous observations (Figure 1D ). ILCregs uniquely express transcription factors, such as Id3 and Sox4 (Figure 2A ), and they also highly expressed Id2, which is required for development of ILCs (Diefenbach et al., 2014; Spits and Cupedo, 2012) . However, ILCregs lack typical transcription factors of other ILCs and Tregs, such as Rorc (encoding RORgt), Tbx21 (encoding T-bet), Gata3, and Foxp3, respectively (Serafini et al., 2015) . Intriguingly, ILCregs constitutively express Tgfbr1, Tgfbr2, Il2rb, and Il2rg (Figure 2A ), suggesting they responded to TGF-b and IL-2 signaling. Principal component analysis further verified that ILCregs harbor a unique gene profile ( Figure 2B ). Similarly, human ILCregs show distinct gene profiles of transcription factors and cytokines compared to other ILCs ( Figure 2C ). Additionally, some feature cytokines, such as IL-10 and transforming growth factor b1 (TGF-b1), are also highly expressed in human ILCregs as well.
High expression levels of TGF-bRI, TGF-bRII, IL-2Rb, and Id2 (inhibitor of DNA binding 2) in ILCregs were validated by flow cytometry ( Figures S1F and S1G Figure S1 .
mice abrogated ILCregs ( Figure S1H ), which are common characters similar to other ILC subsets (Serafini et al., 2015 Figure S2E ), suggesting ILCregs were generated from the progenitor CHILP (Klose et al., 2014) . However, deletion of PLZF-or RORgt-expressing cells does not affect the development of ILCregs ( Figure S2E ), indicating that ILCregs do not differentiate from the progenitor of LTi, ILC1, ILC2, or ILC3 cells (Artis and Spits, 2015) . To further verify the progenitor of ILCregs, we transferred CLP, aLP, CHILP, and ILCP progenitors into Rag1
Il2rg
À/À mice for adoptive transfer assays. We noticed that CLP, aLP, and CHILP were able to produce ILCregs, whereas ILCPs could not generate ILCregs ( Figure S2F ). Depletion of CHILPs by DT treatment in adoptively reconstituted Rag1 Figure 3A) . Notably, ILCregs gradually expanded in the intestines during the process of inflammation ( Figures 3B,  3C , and S3A), reaching a peak level at 8 days post-stimulation, which came up at peak inflammation ( Figure S3B ). By contrast, the number of ILC1s and ILC3s immediately increased at early stages post-stimulation and decreased soon afterward ( Figure S3C ), whereas the number of ILC2s did not change during the process of inflammation ( Figure S3C ). These data indicate that ILCregs can be induced by innate intestinal inflammation. It has been reported that IL-10-deficient mice display spontaneous colitis (Josefowicz et al., 2012; Kü hn et al., 1993) . Since IL-10 was a signature cytokine of ILCregs, we then generated Rag1 Figure S3F ). We observed that ILCreg transfer was able to prevent pathogenic innate colitis of their rescued Rag1 Figures 3D-3F ). Finally, ILCreg transfer exhibited a higher survival rate with DSS treatment ( Figure 3G ). Similar observations were achieved by infection with S. typhimurium (Figures S3G and S3H) . Collectively, ILCregs are able to protect mice from innate immune colitis.
ILCregs Produce IL-10 and TGF-b1 during Intestinal Inflammation Next, we analyzed cytokine expression profiles of ILCregs in Rag1 À/À mice during inflammatory stimulation. We observed that ILCregs in Rag1 À/À mice generated high levels of IL-10
and TGF-b1 after treatment with the previously used stimuli See also Figure S4 and Table S1 .
ILCs to prevent innate immune responses. We isolated ILCregs from sLP of DSS-treated mice and incubated them with activated ILC1s, ILC2s, and ILC3s, respectively. We noticed that ILCregs were able to inhibit cytokine secretion by ILC1s (IFN-g) and ILC3s (IFN-g and IL-17A), but not by ILC2s ( Figures 4D,  4E , S4C, and S4D). Of note, anti-IL-10 antibody treatment abrogated inhibitory roles of ILCregs ( Figures 4D and 4E ). However, ILCregs failed to suppress IL-22 secretion by ILC3s ( Figures  S4E and S4F ). Furthermore, IL-10 alone could suppress the activation of ILC1s and ILC3s ( Figures 4D and 4E ). Of note, via titration assays, ILCregs effectively inhibited the activities of ILC1/3 at ratios around 1:2 to 2:1 ( Figure S4G ). Ki67 and CD69 are two feature molecules that denote the activation of ILCs (Munneke et al., 2014) . We found that ILCregs also inhibited the expression of Ki67 and CD69 on activated ILC1s and ILC3s, respectively (Figures 4F and 4G) . By contrast, addition of TGF-b1 did not impact the activation of ILC1s and ILC3s (Figures S4H and S4I) . These data indicate that ILCregs suppress the activation of ILC1s and ILC3s via secretion of IL-10.
ILCregs Suppress the Activation of ILC1s and ILC3s via Secretion of IL-10
To further validate the inhibitory role of ILCregs in vivo, we generated Rag1 
Il2rg
À/À mice ( Figure S6K ). With DT treatment, ILCregs were almost lost in engrafted Rag1 Figure S6O ). We conclude that ILCregs play an inhibitory role in the regulation of innate immunity.
Id3 Is Required for the Development of ILCregs
Based on our above microarray analysis (Figure 2A ), ILCregs uniquely, highly expressed the translational regulator Id3 (inhibitor of DNA binding 3). Id3 belongs to the Id family members that contain an HLH dimerization domain but lack the basic DNAbinding region. The Id proteins (Id1-4) modulate the DNA-binding activity of E proteins that act as transcriptional activators or repressors (Rivera et al., 2000) . Accumulating evidence shows that Id2 and Id3 play critical roles in regulating the developmental progression of T cells (Li et al., 2004; Miyazaki et al., 2014 Figure 6D ). Of note, deficiency of Id3 abrogated ILCreg population and displayed severe colitis, which could be attenuated by rescue of WT ILCregs ( Figures 6E and 6F) . Activation of ILC1/3s was weakened after adoptive transfer of ILCregs ( Figure 6G ), indicating that deficiency of Id3 impairs ILCreg-related functions. We conclude that Id3 is a unique fate determination factor to drive the development and/or maintenance of ILCregs.
Autocrine TGF-b1 Is Required for the Expansion of ILCregs during Inflammation Next, we wanted to examine which cytokine signaling induced the development and/or maintenance of ILCregs. As ILCregs expressed high levels of IL-2R and TGF-bR ( Figure S1F ), we then isolated ILCregs from IL-10-GFP reporter mice and incubated them with common g-chain-related cytokines and TGF-b1. We noticed that IL-2 and TGF-b1 were able to promote expansion of ILCregs ( Figure 7A ), suggesting that IL-2 and TGF-b signaling are required for the proliferation and/or maintenance of ILCregs. Above, we demonstrated that TGF-b1 was induced in ILCregs during innate immune responses ( Figures 4A-4C Figure S7A ). Of note, numbers of CD45.1 and CD45.2 hematopoietic progenitors were comparable ( Figure S7B ). These data suggest that autocrine TGF-b1 is dispensable for the development of ILCregs. After treatment with DSS, the number of WT ILCregs (CD45.1) increased 2-fold in transplanted recipient mice compared to that with non-DSS treatment ( Figure S7A) . However, the number of TGF-b1-deleted ILCregs (CD45.2) dramatically reduced post-DSS treatment ( Figure S7A ). These data indicate that autocrine TGF-b1 is required for the expansion and survival of ILCregs during innate immune responses.
Next, we generated Tgfb1 flox/flox ;CreERT2;IL-10-GFP mice to determine the role of TGF-b1 secreted by ILCregs in their expansion. We then isolated ILCregs from Tgfb1 flox/flox ;CreERT2;IL-10-GFP mice and incubated them in media containing IL-2 following treatment with 4-hydroxytamoxifen (4-HT). With administration of 4-HT, ILCregs abrogated TGF-b1 production ( Figure 7B) . Consequently, the numbers of ILCregs were dramatically reduced ( Figure 7C ), suggesting autocrine TGF-b1 is required for the expansion of ILCregs.
To further verify TGF-b1 acted as an autocrine manner in vivo, we transferred Tgfb1 flox/flox ;CreERT2;IL-10-GFP ILCregs, together with ILC1s and ILC3s, into Rag1
Il2rg
À/À mice (Figure 7D ). After administration of TMX, ILCregs were almost abolished in the intestine with DSS stimulation ( Figures 7D, 7E , and S7C). These observations were further validated by in situ immunofluorescence staining ( Figure 7F ). Moreover, TMX-treated mice lost body weight quickly and displayed more severe colitis with DSS treatment (Figures 7G-7J ). Finally, these mice produced substantial amounts of IFN-g and IFN-g/IL-17A by respective ILC1s and ILC3s ( Figure 7K ). Similar results were obtained by S. typhimurium infection ( Figures S7D and S7E ). Altogether, autocrine TGF-b1 by ILCregs sustains the maintenance/ survival and expansion of inflammation-activated ILCregs. The TGF-b receptor complex is a tetrameric structure, consisting of two type I TGF-b receptors (TGF-bRI) and two type II TGF-b receptors (TGF-bRII) (Travis and Sheppard, 2014) . Deletion either of them is able to abrogate TGF-b signaling (Kang et al., 2009) . We generated Tgfbr2 flox/flox ;CreERT2;IL-10-GFP mice and performed adoptive transfer assays ( Figure S7F ). After TMX treatment, ILCregs almost lost in the intestine over DSS treatment ( Figure S7G ). Consequently, Tgfbr2 abrogation in ILCregs led to more severe colitis and more persistent intestinal damage ( Figures S7H and S7I ). In parallel, these Tgfbr2-deficient mice exhibited active ILC1s and ILC3s ( Figure S7J ). Therefore, TGF-b1 signaling is required for the expansion and survival of ILCregs.
DISCUSSION
It has been reported that innate lymphoid cells (ILCs) play important roles in innate immunity (Spits and Cupedo, 2012) . ILCs are able to cause inflammation independent of T and B cells (Buonocore et al., 2010; Coccia et al., 2012; Powell et al., 2012 (Eberl et al., 2015) . Many studies reported that lack or dysfunction of ILCs by deletion of key transcription factors or signaling factors causes apparent pathologic disorders (Guo et al., 2015; Rankin et al., 2013; Spooner et al., 2013) . Like all the immune responses, the activation of these cells also needs to be balanced by stringent regulations because the excessive activation may result in tissue Figure 7 . Autocrine TGF-b1 Is Required for the Expansion of ILCregs (A) ILCregs from IL-10-GFP mice were isolated, treated with indicated cytokines (2 ng/ml murine IL-2, 5 ng/ml murine IL-4, 5 ng/ml murine IL-7, 5 ng/ml murine IL-9, 5 ng/ml murine IL-15, 5 ng/ml murine IL-21, 5 ng/ml murine IL-10, and 5 ng/ml murine TGF-b1), and analyzed by flow cytometry. Fold changes of cell numbers were analyzed and are shown as means ± SD. A recent study reported that ILC2s are involved in lung inflammation (Monticelli et al., 2016) . Whether ILCregs exert tissue-specific regulation needs to be further investigated. Tolerance in the intestine relies on a wide array of independent immunosuppressive mechanisms. Accumulating evidence indicates that Tregs are able to utilize multiple mechanisms to inhibit immune responses in intestinal inflammation (Asseman et al., 1999; Izcue et al., 2009) . Tregs can suppress the activation of other T cells either directly via a cell-contact-dependent fashion or indirectly through downregulating the activity of antigen-presenting cells (APCs) (Thornton and Shevach, 1998; Vignali et al., 2008) . Tregs secreted effector cytokines, such as IL-10 and transforming growth factor (TGF)-b play a critical role in the regulation of intestinal inflammation (Maloy et al., 2003) . Indeed, IL-10-deficient mice exhibit severe intestinal inflammation and elevated proinflammatory cytokines secretion (Kü hn et al., 1993) . Moreover, polymorphisms at the Il10 locus confer risk for ulcerative colitis and Crohn's disease (Franke et al., 2008 (Franke et al., , 2010 , suggesting that IL-10 exerts a central role in the regulation of intestinal mucosal homeostasis. Here, we show that ILCregs uniquely secrete large amounts of IL-10 to downregulate the effector functions of ILC1s and ILC3s during the innate intestinal inflammation. However, Tregs have no apparent inhibitory roles in the suppression of ILC1s and ILC3s during the innate intestinal inflammation. More importantly, ILCregs were located very closely to ILCs in the small intestine (data not shown). The physical closer distance between ILCregs and ILCs might contribute to the regulatory activity of ILCregs to ILC1s and ILC3s.
Of note, IL-22 exerts a protective role in mucosal immunity Sugimoto et al., 2008) . Here, we found that ILCregs inhibit the generation of IL-17A/IFN-g, but do not impact the production of IL-22 in ILC3s, which is beneficial to the protective function of ILCregs against innate inflammation. Thus, secretion of IL-22 and IL-17A/IFN-g by ILC3s might be separately regulated by ILCregs during the process of inflammation as Th17 cells do (Zheng et al., 2007) . Accumulating evidence indicates that IL-27/IL-27R signaling triggers IL-10 production in a variety of immune cells (Saraiva and O'Garra, 2010) . Here, we demonstrated that ILCregs express low levels of IL-27R, suggesting IL-27/IL-27R signaling may not participate in the regulation of IL-10 production in ILCregs. We observed that ILCregs are activated by IL-2 and TGF-b signaling. It has been reported that IL-2 and TGF-b signaling induces IL-10 generation in Tregs (Brandenburg et al., 2008; Maynard et al., 2007) . Therefore, IL-2 and TGF-b signaling might be involved in the regulation of IL-10 production in ILCregs. How ILCregs induces IL-10 secretion needs to be further investigated.
All ILC lineages are originally derived from common lymphoid progenitors (CLPs) in the bone marrow, which also differentiate into T and B cells (Diefenbach et al., 2014 (Gury-BenAri et al., 2016) . Among these genes they used, however, several ILCreg feature genes were not included. We then chose 112 feature genes for ILCregs and ILCs and re-analyzed the single-cell RNA sequencing (RNA-seq) data (GEO: GSE85152). We noticed that ILCreg subpopulation was virtually clustered and distinct from the three existing ILC subpopulations (data not shown).
Transforming growth factor-b (TGF-b) is a multifunctional cytokine that modulates cell survival, proliferation, and differentiation in a variety of settings ranging from embryogenesis to adult tissue homeostasis (Wu and Hill, 2009 ). TGF-b needs to bind its respective cell surface receptor to initiate TGF-b signaling for its effector functions. The TGF-b receptor complex is a tetrameric structure, consisting of two type I TGF-b receptors (TGF-bRI) and two type II TGF-b receptors (TGF-bRII) (Travis and Sheppard, 2014) , deletion either of which can abrogate TGF-b signaling (Kang et al., 2009) . For instance, TGF-b signaling plays critical roles in preventing uncontrolled immune responses via inducing development of Tregs (Curotto de Lafaille and Lafaille, 2009; Sakaguchi et al., 2008) . A recent study showed that TGF-b signaling is required for the differentiation of salivary gland ILC1s through suppression of Eomes expression (Cortez et al. 2016) . In this study, we show that ILCregs produce large amounts of TGF-b, and this autocrine TGF-b is required for the expansion and maintenance of inflammation-induced ILCregs. More importantly, autocrine TGF-b is dispensable for the development of ILCregs. Whether paracrine TGF-b affects the development and differentiation of ILCregs in the intestine needs to be further investigated.
In sum, we have identified a new distinct regulatory subset of ILC cells (called ILCregs), and ILCregs exert inhibitory functions during the innate immune response, which contributes to resolution of innate intestinal inflammation. Hence, we believe that ILCregs may be used to develop new and potential therapies to restore immune tolerance in chronic inflammatory and autoimmune diseases for their effective treatment.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice and human tissues Rag1 and transferred together with T, B, NK and ILC cells. After 7 days, engrafted cells were confirmed by flow cytometry. Transferred mice were administrated with 100 ng/mouse diphtheria toxin (DT) for every three days and treated with 3% DSS followed by further analysis. Human resected small intestine and colon tissues were obtained from West China Hospital, Sichuan University (Chengdu, China) with informed consent, according to the Institutional Review Board (IRB)-approved protocol.
Generation of inflammation mouse models For DSS-induced colitis, Rag1
À/À mice were treated with 3% DSS in drinking water for the indicated days. For anti-CD40-induced colitis, Rag1 À/À mice were injected with 150 mg anti-CD40 antibody (clone:FGK45, i.p.) on day 0. For bacteria-induced-colitis,
Rag1
À/À mice were infected by oral gavage of 5x10 4 c.f.u. S. Typhimurium (from Institute of Microbiology, Chinese Academy of Sciences) or 1x10 9 c.f.u. C. Rodentium (from Prof. Baoxue Ge, Chinese Academy of Sciences) on day 0. Mice were monitored for indicated days followed by further analysis.
METHOD DETAILS Isolation of ILCreg cells
Intestines from IL-10-GFP mice were cut open longitudinally and Peyer's patches were removed. Next, intestines were cleaned and cut into pieces. Epithelial layers were removed by incubation three times in 5 mM EDTA Ca 2+ and Mg 2+ free Hank's medium for 20 min each at 37 C, and the epithelial cells were collected if needed. Then, intestines were cut into fine pieces and digested twice for 40 min each at 37 C with Collagenase II and III (1 mg/ml; Worthington), DNase I (200 mg/ml; Roche) and dispase (4U/ml; Sigma). Mononuclear cells were isolated with 40%-80% Percol gradient, and washed twice. Lin 
Flow cytometry assay
Intestinal cells were isolated and blocked with anti-CD16/32 antibody for 30 min on ice. Cells were then stained with surface markers for 1 hr on ice. For intracellular cytokine staining, cells were cultured in media containing indicated cytokines in the presence of Brefeldin A for 4 hr at 37 C. Cells were harvested for surface marker staining and fixed and permeablized by Intracellular Fixation & Permeablization buffer set (eBioscience) after surface marker staining, followed by staining with antibodies against intracellular antigens for flow cytometer (FACS Aria III, BD). We used anti-IL-10-PE antibody (JES5-16E3) to stain intracellular IL-10.
Imaging flow cytometry
Lymphocytes from mouse intestines were isolated and blocked with anti-CD16/32 antibody for 30 min. Cells were then stained with antibodies against Lin, CD127, CD45 followed by intracellular staining of IL-10. Nuclei were visualized by DAPI staining. Cells were analyzed by imaging flow cytometer (Amnis ImageStream MakII, Merck), and data were analyzed by IDEAS software (Merck) (Wang et al., 2016a) .
Immunofluorescence assay
For in situ immunofluorescence of ILCreg cells, mouse intestines were treated as previously described (Xia et al., 2016) . Briefly, intestines were cut open longitudinally and fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich) fixative for 8 hr, and rehydrated in 30% sucrose solution for 24 hr and frozen in OCT for sectioning. Intestinal sections were rehydrated in PBS and blocked in 10% donkey serum and anti-CD16/32 antibody. We used anti-IL-10 (ab9969, Abcam, Rabbit) and Biotin-conjugated anti-CD127 (A7R34, eBioscience, Rat) as primary antibodies. After staining with anti-IL-10 and Biotin-conjugated anti-CD127 antibodies for 2 hr at room temperature (RT) we used Alex488-conjugated donkey anti-Rabbit and Alex594-conjugated Streptavidin (Invitrogen) as secondary antibodies. Then, we used APC-conjugated lineage cocktails to stain the slides at RT for 1 hr. After washing for 3 times, nuclei were stained by DAPI if needed and the sections were subjected to dehydrating in EtOH gradient: 70%, 85%, 95%, and 100%. Mounted sections were analyzed by confocal microscopy (Olympus FV1000). + RORgt-GFP + ) were isolated from RORgt-GFP reporter mice (CD45.1). ILCs were activated if needed as follows. ILC1s were cultured in media with IL-12 (10 ng/ml) and IL-18 (10 ng/ml) for 24 hr. ILC3s were cultured in media with IL-23 (10 ng/ml) for 24 hr. 5x10
Adoptive transfer assays
4 ILCs alone or with 5x10 4 ILCregs were adoptively transferred into Rag1
Il2rg
À/À mice. After 7-14 days, transferred mice were analyzed or treated with 3% DSS with or without administration of tamoxinfen (TMX) (50 mg/kg i.p. for five consecutive days) for indicated days for further assays.
ELISA assay
ILCregs or ILCs from mice with indicated treatment were isolated and cultured in complete media for 24 hr. Supernatants were collected and cytokines were analyzed by ELISA kit (eBioscience) by manufacturer's instructions. Detection thresholds of different cytokines were 50 pg/ml for IFN-g, 50 pg/ml for IL-17A, 75 pg/ml for IL-22, 50 pg/ml for IL-4, 75 pg/ml for IL-5, 50 pg/ml for IL-13 and 50 pg/ml for TGF-b1. Values below detection thresholds were shown as ND (not detectable). The ELISA data were normalized to total cell numbers and shown as means ± SD per 5x10 3 cells.
Histology and immunohistochemistry assay
Mouse colons were cut open longitudinally and fixed in 4% paraformaldehyde (PFA) (Sigma-Aldrich) fixative for 8 hr for 12 hr. Fixed tissues were washed for twice using 75% ethanol and embedded in paraffin, followed by sectioning and staining with hematoxylin and eosin (H&E) according to standard laboratory procedures. Immunohistochemistry assay was performed as previously described (Wang et al., 2016a) . Briefly, small intestines from mice were fixed in 4% PFA for 12 hr. Fixed tissues were rehydrated in 30% sucrose solution for 24 hr and frozen in OCT for sectioning. Intestine sections were blocked with H 2 O 2 and anti-CD16/32 antibody and then stained with primary antibodies (anti-Lin, eBioscience, and anti-IL-10 antibodies, Abcam) and subjected to double immunohistochemistry staining with Polymer-HRP and AP Kit from GBI Labs according to the manufacturer's instructions.
Colitis scores and histologic analysis
Colons of indicated mice were cut open longitudinally and fixed in 4% PFA followed by paraffin sectioning and H&E staining. A combined colitis score was calculated based on weight loss, appearance of the stool, intestinal bleeding, and histology (Gagliani et al., 2015) . Weight loss was analyzed as follows: 0, 0%-4% weight loss or weight gain; 1, 4%-10% weight loss; 2, 10%-15% weight loss; 3, 15%-20% weight loss; 4, more than 20% weight loss. Appearance of the stool was scored as follows: 0, normal; 1, soft but still formed; 2, very soft; 3, diarrhea. Intestinal bleeding was assessed as follows: 0, negative hemoccult; 1, positive hemoccult; 2, blood traces in stool visible; 3, rectal bleeding. Scoring system for inflammation-associated histological changes are as follows: 0, no evidence of inflammation; 1, low level of inflammation with scattered infiltrating mononuclear cells (1-2 foci); 2, moderate inflammation with multiple foci; 3, high level of inflammation with increased vascular density and marked wall thickening; 4, maximal severity of inflammation with transmural leukocyte infiltration and loss of goblet cells.
Generation of IL-10 deficient ILCregs
ILCregs from Rosa26-STOP-Cas9;Id2-CreERT2;IL-10-GFP mice were isolated and infected with lentivirus (lentiGuide-Puro-sgRNAIl10) carrying sgRNA against Il10 gene (#1: 5 0 -TATTGTCTTCCCGGCTGTAC-3 0 ; #2: 5 0 -GCATGTGGCTCTGGCCGACT-3 0 ). Infected cells were selected with 1 mg/ml puromycin (Invivogen) and transferred into Rag1 À/À Il2rg À/À mice together with respective WT (CD45.1) lymphocytes. IL-10 expression in ILCregs (CD45.2) after treatment with 0.5 mm 4-hydroxytamoxinfen (4-HT) was detected prior to transplantation.
Electron microscopy
For transmission electron microscopy (TEM), ILCregs were isolated from IL-10-GFP mice and treated as previously described (Wang et al., 2016b) . In brief, cells were fixed with 2.5% glutaraldehyde on ice for 2 hr followed by fixation in 2% osmium tetroxide. Briefly, cells were immersed in EPON812 resin after dehydrating with sequential washes in 50, 70, 90, 95 and 100% ethanol. Ultrathin sections were collected on copper grids and counterstained using uranyl acetate and lead citrate. Images were taken with a Tecnai spirit transmission electron microscope (FEI).
Real-time PCR assay
ILCreg cells were isolated from treated mice, mRNA was extracted by using Neasy Micro Kit (QIAGEN) according to the manufacturer's instructions. mRNA quality was determined by A260/A280 (between 1.8 and 2.2) and A260/230 (> 1.7) ratios. RNA integrity was assessed by agarose gel electrophoresis. cDNAs were synthesized by using oligo dT followed by real-time PCR. Primers for real-time PCR in this study are as shown in Table S1 .
Microarray analysis
Live ILCregs from IL-10-GFP mice were isolated by Magnetic Cell Sorting system (MACS, Miltenyi Biotec) and flow cytometer (FACS Aria III, BD). Purity of cells was over 95% that was determined by post sorting analysis with flow cytometry. Total RNA was extracted from ILCregs using standard RNA extraction protocol, followed by DNase incubation to remove nuclear DNA. RNA quality was monitored by NanoDrop ND-1000 and RNA integrity was tested by agarose gel electrophoresis. Total RNA was amplified with Whole Transcript (WT) Pico Reagent Kit (Affymetrix). Microarray assay was performed as described previously (Xia et al., 2014) . Briefly, total RNA was subjected to labeling and array hybridization using GeneChip Mouse Transcriptome Array 1.0 according to manufacturer's instructions (Affymetrix). Hybridized GeneChips were washed and stained in the Affymetrix Fluidics Station 450. GeneChips were scanned by using Affymetrix GeneChip Command Console (AGCC) that installed in GeneChip Scanner 3000 7G. Data were analyzed with Robust Multichip Analysis (RMA) algorithm using Affymetrix default analysis settings. Values presented are log 2 RMA signal intensity. For human ILCregs, lymphocytes were isolated from human normal intestinal tissues from resected small intestines and Lin -CD45 + cells were then enriched by MACS (Lin = CD2, CD3, CD14, CD16, CD19, CD56, CD235a). Enriched cells were stained with Lineage cocktail, anti-CD45, and anti-CD127 antibodies followed by intracellular staining of IL-10. Lin -CD45 + CD127 + IL-10 + cells were isolated and subjected to RNA extraction with RNeasy FFPE Kit (QIAGEN). Total RNA was amplified with Whole Transcript (WT) Pico Reagent Kit (Affymetrix). Microarray assay was performed by using GeneChip Human Transcriptome Array 2.0 according to manufacturer's instructions (Affymetrix).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
For statistical analysis, data were analyzed by using Sigma Plot or GraphPad Prism 7.0. Two-tailed unpaired Student's t test, Non parametric Mann-Whitney U-test or One way ANOVA were used according to the type of experiments. Kaplan-Meier method was used for comparison of survival probabilities. P-values % 0.05 were considered significant (*, p < 0.05; **, p < 0.01; ***, p < 0.001); p > 0.05, non-significant (NS). All flow cytometry data were analyzed with FlowJo (Treestar). No statistical methods were used to predetermine sample size.
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